-$0.14 EPS Expected for Ironwood Pharmaceuticals, Inc. (IRWD) This Quarter
Equities research analysts expect that Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) will post earnings per share of ($0.14) for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Ironwood Pharmaceuticals’ earnings, with estimates ranging from ($0.18) to ($0.06). Ironwood Pharmaceuticals also posted earnings of ($0.14) per share during the same quarter last year. The company is expected to report its next quarterly earnings results on Thursday, February 21st.
According to Zacks, analysts expect that Ironwood Pharmaceuticals will report full-year earnings of ($0.94) per share for the current year, with EPS estimates ranging from ($1.09) to ($0.72). For the next financial year, analysts anticipate that the company will report earnings of $0.27 per share, with EPS estimates ranging from ($0.12) to $0.74. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Ironwood Pharmaceuticals.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.24). The business had revenue of $68.69 million for the quarter, compared to analyst estimates of $93.48 million. During the same period last year, the firm posted ($0.18) EPS. The firm’s revenue for the quarter was down 20.9% on a year-over-year basis.
NASDAQ IRWD traded down $0.20 during trading on Monday, hitting $11.88. 1,677,504 shares of the company’s stock traded hands, compared to its average volume of 1,784,796. Ironwood Pharmaceuticals has a 12-month low of $11.62 and a 12-month high of $21.20. The firm has a market cap of $1.83 billion, a price-to-earnings ratio of -12.77 and a beta of 1.33.
In related news, Director Julie Mchugh sold 1,500 shares of the stock in a transaction dated Wednesday, September 5th. The shares were sold at an average price of $19.10, for a total value of $28,650.00. Following the completion of the transaction, the director now directly owns 91,131 shares of the company’s stock, valued at $1,740,602.10. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Mark G. Currie sold 116,651 shares of the stock in a transaction dated Friday, October 5th. The stock was sold at an average price of $17.53, for a total transaction of $2,044,892.03. Following the completion of the transaction, the insider now directly owns 70,680 shares of the company’s stock, valued at $1,239,020.40. The disclosure for this sale can be found here. Over the last three months, insiders sold 248,339 shares of company stock valued at $4,475,466. 7.63% of the stock is owned by insiders.
Hedge funds have recently added to or reduced their stakes in the stock. Meeder Asset Management Inc. bought a new position in Ironwood Pharmaceuticals in the second quarter worth about $186,000. A.R.T. Advisors LLC purchased a new stake in Ironwood Pharmaceuticals in the first quarter worth about $208,000. Campbell & CO Investment Adviser LLC purchased a new stake in Ironwood Pharmaceuticals in the third quarter worth about $249,000. V Wealth Management LLC purchased a new stake in Ironwood Pharmaceuticals in the second quarter worth about $258,000. Finally, PNC Financial Services Group Inc. grew its holdings in Ironwood Pharmaceuticals by 17,621.9% in the second quarter. PNC Financial Services Group Inc. now owns 17,013 shares of the biotechnology company’s stock worth $325,000 after purchasing an additional 16,917 shares during the period. 97.29% of the stock is owned by institutional investors.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout in adults under the ZURAMPIC and DUZALLO names.
Recommended Story: What do investors mean by earnings per share?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.